US 12,465,583 B2
Methods of treatment using an mTORC1 modulator
Steven Leventer, Boston, MA (US); and Steven D. Targum, Boston, MA (US)
Assigned to Navitor Pharmaceuticals, Inc., Boston, MA (US)
Filed by Navitor Pharmaceuticals, Inc., Boston, MA (US)
Filed on Jun. 29, 2023, as Appl. No. 18/216,307.
Application 18/216,307 is a continuation of application No. 17/086,639, filed on Nov. 2, 2020, granted, now 11,723,890.
Claims priority of provisional application 62/929,449, filed on Nov. 1, 2019.
Prior Publication US 2024/0041811 A1, Feb. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/198 (2006.01); A61K 9/00 (2006.01); A61P 25/24 (2006.01)
CPC A61K 31/198 (2013.01) [A61K 9/0053 (2013.01); A61P 25/24 (2018.01)] 21 Claims
 
1. A method of treating depression in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a pharmaceutically acceptable composition comprising compound A:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof;
wherein the therapeutically effective amount comprises a total daily dose of about 100 mg to about 3000 mg.